Candriam S.C.A. Sells 11,524 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

Candriam S.C.A. lessened its stake in shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) by 4.8% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 227,476 shares of the company’s stock after selling 11,524 shares during the period. Candriam S.C.A. owned 0.36% of MoonLake Immunotherapeutics worth $12,318,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in MLTX. US Bancorp DE purchased a new stake in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at about $44,000. Barclays PLC raised its position in shares of MoonLake Immunotherapeutics by 1,269.2% during the 3rd quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after buying an additional 5,229 shares in the last quarter. Erste Asset Management GmbH purchased a new stake in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at about $741,000. Y Intercept Hong Kong Ltd raised its position in shares of MoonLake Immunotherapeutics by 55.4% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 20,325 shares of the company’s stock valued at $1,025,000 after buying an additional 7,247 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in shares of MoonLake Immunotherapeutics by 1.9% during the 3rd quarter. GSA Capital Partners LLP now owns 22,127 shares of the company’s stock valued at $1,116,000 after buying an additional 403 shares in the last quarter. Institutional investors own 93.85% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on MLTX. Needham & Company LLC upped their target price on shares of MoonLake Immunotherapeutics from $62.00 to $66.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. The Goldman Sachs Group reduced their price objective on shares of MoonLake Immunotherapeutics from $82.00 to $73.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. Finally, HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, February 27th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $83.20.

MoonLake Immunotherapeutics Stock Performance

Shares of NASDAQ:MLTX opened at $38.03 on Friday. The firm has a market cap of $2.43 billion, a PE ratio of -29.48 and a beta of 1.31. The firm’s 50 day simple moving average is $45.10 and its 200-day simple moving average is $48.64. MoonLake Immunotherapeutics has a one year low of $37.55 and a one year high of $58.26.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last issued its earnings results on Wednesday, February 26th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.09). Equities research analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.